Statement from the Alliance for Pharmacy Compounding on FDA Proposed Rule Regarding 503B Bulks List
APC is reviewing the FDA’s proposed rule addressing the 503B Bulks List, including the proposal not to include liraglutide, semaglutide, and ...
Being an exceptional compounding professional means you never stop learning
We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
APC is reviewing the FDA’s proposed rule addressing the 503B Bulks List, including the proposal not to include liraglutide, semaglutide, and ...
State updates on the latest bills and policy impacting compunding pharmacists.
Karla Palmer and Charlie Snow of Hyman, Phelps & McNamara published a two-part primer on the peptide compounding landscape. Explore it here.
HHS Secretary Kennedy testified before the House Energy & Commerce Committee this week, and compounding came up twice. Here's what he said.
Harmed patients deserve answers, not assumptions. We explore APC's Scott Brunner's thoughts.